Search

• The Meet-URO 23/I-RARE study is a retrospective and prospective study on rare genitourinary cancer. • We enrolled 37 patients with collecting duct carcinoma (CDC), male:female ratio: 3:1. • Seven patients were metastatic at diagnosis. 33 patients received first-line therapy, 4 only nephrectomy. • We confirmed the dismal prognosis of CDC, with a median overall survival (OS) of 22.1 months. • The median relapse-free survival was 3.7 months, while median progression-free survival (PFS) was 3.3 months. • PFS appeared to be longer in female and in patients with a good performance status (PS). • A better OS was reported in female patients and in patients with a good PS. Rare genitourinary tumors are lacking of randomized and observational data. We aimed to describe the clinical characteristics and outcomes of patients with collecting duct carcinoma (CDC) through the Meet-URO 23/I-RARE database. We performed a multicentric retrospective-prospective study within the Meet-URO network, enrolling patients from March 2021 (retrospectively up from 2011) until March 2023. The primary objective was to describe the clinical characteristics of patients with CDC, the secondary objectives were to assess the oncological outcomes in terms of relapse-free survival (RFS), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) to treatment. 37 patients with CDC were enrolled. Four patients underwent only surgery, 33 received first-line systemic therapy. Median OS was 22.1 months (95% CI, 8.9-31.9). Median RFS for patients with localized disease at onset (n = 30) was 3.7 months (95% CI, 1.9-12.8), median PFS for first-line treatment was 3.3 months (95% CI, 2.7-9.9), with an ORR of 27%. Female sex and good performance status (PS) were associated with longer PFS (P =.072 and P <.01, respectively) and OS (P =.030 and P =.141, respectively). Patients with CDC had dismal prognosis, with scarce benefit from the available treatments. Female sex and good PS seemed to be associated with better prognosis. The Meet-URO 23/I-RARE is a retrospective-prospective study on rare genitourinary cancer. This analysis described the characteristics and outcomes of 37 patients with collecting duct carcinoma. Median overall survival (OS) was 22.1 months and median progression-free survival (PFS) for first-line treatment was 3.3 months. Female sex and good performance status seemed associated to longer OS (p =.030) and PFS (p <.01), respectively. [ABSTRACT FROM AUTHOR]

The objective of this review was to summarize published radiomics studies dealing with infradiaphragmatic cancers, blood malignancies, melanoma, and musculoskeletal cancers, and assess their quality. PubMed database was searched from January 1990 to February 2022 for articles performing radiomics on PET imaging of at least 1 specified tumor type. Exclusion criteria includd: non-oncological studies; supradiaphragmatic tumors; reviews, comments, cases reports; phantom or animal studies; technical articles without a clinically oriented question; studies including <30 patients in the training cohort. The review database contained PMID, first author, year of publication, cancer type, number of patients, study design, independent validation cohort and objective. This database was completed twice by the same person; discrepant results were resolved by a third reading of the articles. A total of 162 studies met inclusion criteria; 61 (37.7%) studies included >100 patients, 13 (8.0%) were prospective and 61 (37.7%) used an independent validation set. The most represented cancers were esophagus, lymphoma, and cervical cancer (n = 24, n = 24 and n = 19 articles, respectively). Most studies focused on 18F-FDG, and prognostic and response to treatment objectives. Although radiomics and artificial intelligence are technically challenging, new contributions and guidelines help improving research quality over the years and pave the way toward personalized medicine. [ABSTRACT FROM AUTHOR]

Context An oligometastatic state is an early event during tumor metastatic spread and is rarely reported in patients with genitourinary tumors. In this condition, the primary tumor has low capacity for distal dissemination because its aggressiveness has not yet reached a maximum. Objective To review recent findings on the diagnosis and treatment of oligometastatic disease in patients with genitourinary tumors. Evidence acquisition To identify relevant studies, we reviewed articles in PubMed from January 1966 to September 2017. The search was conducted by combining the words “oligometastasis” or “oligometastatic disease” with “bladder cancer”, “genitourinary tumor”, “prostate cancer”, and “renal cancer”. Evidence synthesis In renal cell carcinoma (RCC), tumors from patients with multiple metastases showed a different gene signature compared to oligometastatic RCC. In addition, an oligometastatic state was an independent prognostic factor for overall survival (OS). Otherwise, the characteristics of oligometastases from bladder cancer remain unclear, as do the clinical and prognostic significance of metastasectomy in this setting. However, patients with oligometastatic prostate cancer have longer recurrence-free survival and OS and seem to benefit from local metastasis-directed therapies. Conclusions Early detection of oligometastatic disease in patients with genitourinary tumors is fundamental in improving outcomes by identifying patients who would benefit from local approaches with potentially curative rather than palliative intent. [ABSTRACT FROM AUTHOR]

The objective of the present study is to characterize genitourinary tumors (GU) metastatic to the head and neck and to determine long-term prognoses. Using a retrospective chart review of 734 patients treated between January 1995 and May 2005 with an ICD-9 code pertaining to a metastatic head and neck cancer, we found 37 patients with primary GU tumors. There were 24 cases of prostate cancer, 10 cases of renal cell carcinoma, and 4 cases of transitional cell carcinoma. Sixteen of 24 patients (67%) with prostate cancer had a cranial metastasis while 6 of 9 (67%) patients with renal cell carcinoma had cerebral metastasis. We concluded that prolonged survival is possible in prostate cancer patients treated aggressively with radiation and chemotherapy, indicating that early detection and aggressive screening are important in these patients. [ABSTRACT FROM AUTHOR]

Objective: To clarify how popularly the minimally invasive surgeries for urological tumors are currently conducted in Japan and to predict future trends. Methods: A nation-wide survey was performed by the Japanese Association for Minimum-Incision Endoscopic Surgery under the support of the Japanese Urological Association (JUA). A questionnaire was sent to 1186 JUA-certified educational institutions asking about surgical practices for representative urological tumors performed in 2005 and those to be performed in the near future. Surgical modalities were categorized into open, laparoscopic and minimized-incision surgeries, defined as that the operator considers the incision to be minimal and including minimum-incision endoscopic surgery but not limited. Results: 506 of the 1186 institutions (43%) responded and 20 193 surgical procedures were reported with radical prostatectomy being most frequently performed. Overall 20% and 6% of the procedures were performed with laparoscopic and minimized-incision surgeries, respectively. More than 20% of the respondents performed open surgery with reduced incision size than before. Surgical procedures without inserting fingers or hand were reported in 5–11% of the open surgeries and 33–45% of the minimized-incision surgeries. Endoscopy was utilized in 4–14% of the open surgeries and 24–59% of the minimized-incision surgeries. There was no difference in the incidence of complications among the surgical modalities. 40% and 27% of the respondents are aiming at laparoscopic surgery and at minimized-incision surgery, respectively. Conclusions: The results of this nation-wide survey indicate that minimally invasive surgeries, currently performed in 26% of urological tumor surgeries, are aimed at by the majority of the survey respondents. [ABSTRACT FROM AUTHOR]

Background: Extra-adrenal paragangliomas (PGLs) are infrequent, benign, and neuroendocrine tumors arising from chromaffin cells of the autonomic nervous system. Most PGLs are sporadic, but up to 32% are associated with inherited syndromes such as neurofibromatosis type 1, von Hippel-Lindau disease, and familial PGL. Although most PGLs develop above the umbilicus, they have been reported in the genitourinary (GU) tract. Owing to the paucity of literature on the rates of GU PGL, the objective of our study is to describe the demographic, pathologic, and clinical characteristics of GU PGL, and compare them to non-GU sites of PGL using the surveillance, epidemiology, and end results (SEER) database.Methods: The SEER 18 database was used to identify all cases of PGL from 2000 to 2012. Demographic, pathologic, and clinical characteristics were described using chi-square and t-test for categorical and continuous variables, respectively. The Kaplan-Meier method was used to compare overall survival (OS) between GU and non-GU PGL. Statistical significance was defined as P<0.05. All analyses were performed using excel and SAS/Stat version 9.4.Results: A total of 299 cases of PGL were retrieved from SEER, and 20 (6.7%) of the total PGL arose from the GU tract. The mean age at diagnosis was higher in non-GU than GU PGL (50.4±17.2 vs. 40.8±15.6, P = 0.026). Furthermore, 75% of GU PGLs developed in the bladder, followed by the kidneys/renal pelvis, and spermatic cord (20%). Non-GU PGL developed most frequently within the endocrine system (43%). PGL, overall, was more common in men than in women, and it was more common in whites than all other races. Although 55.5% of GU PGLs were organ confined, only 22.2% of non-GU PGLs were localized at diagnosis. All cases of PGL were treated with surgery. There were 2 cause-specific deaths in the GU PGL groups between 2000 and 2012. The 5-year OS was 93.3% for GU PGL vs. 65.5% in non-GU PGL (P = 0.062).Conclusions: GU PGL remains rare with low incidence (6.7% of all PGL cases) in the US population between 2000 and 2012. Bladder PGL represents just 5% of all PGL. Moreover, GU PGL had better OS compared to PGL developing outside of the GU tract although the P-value only approached statistical significance. The bladder represents the most common site of involvement, and surgery is the mainstay of treatment for GU PGL. Clearer prognostic factors, including tumor grade and stage, are needed to better elucidate PGL management in the future; thus, pooled studies from various institutions with detailed clinical information are needed to delineate these prognostic factors. [ABSTRACT FROM AUTHOR]

Introduction: GATA binding protein 3 (GATA3) is a transcription factor, which belongs to a distinct family of tumor suppressor genes. It is involved in human cancer cell growth and differentiation, and plays an important role in cell proliferation and apoptosis. Although, its expression has been reported in various cancers, there are limited data in genitourinary malignancies. Recent studies found GATA3 to be a sensitive marker for urothelial carcinoma (UC) and associated with prognostic pathologic features. Its level of expression was found to be an independent factor predicting cancer recurrence.Methods and Materials: In this article, immunohistochemical evaluation of GATA3 expression in genitourinary malignancies (invasive UC, renal cell carcinoma, and prostatic adenocarcinomas) was performed.Results: GATA3 was positive in 56/79 (70.8%) of invasive UC, and was negative in all renal cell carcinoma and prostatic adenocarcinomas. The pattern of GATA3 staining, when positive, was intensely nuclear within the clusters of malignant cells. No cytoplasmic staining was noted. Negative controls were all negative. High GATA3 expression was associated with larger tumor size in invasive UC (3.19cm vs. 1.65cm, P = 0.01). GATA3 expression did not correlate with other clinicopathologic parameters in UC.Conclusions: This data suggest that GATA3 is a sensitive marker in confirming invasive UC, and may be helpful in differentiating it from metastatic tumors of renal and prostatic origin. Furthermore, strong GATA3 expression was noted to have an effect on tumor size in patients with UC. [ABSTRACT FROM AUTHOR]